HRP20120665T1 - Farmaceutski pripravci od rifaksimina - Google Patents
Farmaceutski pripravci od rifaksimina Download PDFInfo
- Publication number
- HRP20120665T1 HRP20120665T1 HRP20120665AT HRP20120665T HRP20120665T1 HR P20120665 T1 HRP20120665 T1 HR P20120665T1 HR P20120665A T HRP20120665A T HR P20120665AT HR P20120665 T HRP20120665 T HR P20120665T HR P20120665 T1 HRP20120665 T1 HR P20120665T1
- Authority
- HR
- Croatia
- Prior art keywords
- controlled release
- oral pharmaceutical
- pharmaceutical preparation
- cellulose
- release according
- Prior art date
Links
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical group OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title claims 7
- 229960003040 rifaximin Drugs 0.000 title claims 7
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000013270 controlled release Methods 0.000 claims 24
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 23
- -1 polysiloxanes Polymers 0.000 claims 12
- 238000011282 treatment Methods 0.000 claims 11
- 206010012735 Diarrhoea Diseases 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 7
- 229920002678 cellulose Polymers 0.000 claims 6
- 235000010980 cellulose Nutrition 0.000 claims 6
- 238000011321 prophylaxis Methods 0.000 claims 6
- 239000001913 cellulose Substances 0.000 claims 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 4
- 208000001848 dysentery Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 235000010443 alginic acid Nutrition 0.000 claims 3
- 229920000615 alginic acid Polymers 0.000 claims 3
- 150000001720 carbohydrates Chemical group 0.000 claims 3
- 235000014633 carbohydrates Nutrition 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 230000001276 controlling effect Effects 0.000 claims 3
- 210000002249 digestive system Anatomy 0.000 claims 3
- 239000010410 layer Substances 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 3
- 229940069328 povidone Drugs 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical class CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 241000193163 Clostridioides difficile Species 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012742 Diarrhoea infectious Diseases 0.000 claims 2
- 208000012258 Diverticular disease Diseases 0.000 claims 2
- 206010013554 Diverticulum Diseases 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 229920002907 Guar gum Polymers 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 229920000161 Locust bean gum Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 208000002389 Pouchitis Diseases 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 229920002494 Zein Polymers 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000000783 alginic acid Substances 0.000 claims 2
- 229960001126 alginic acid Drugs 0.000 claims 2
- 150000004781 alginic acids Chemical class 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 230000035587 bioadhesion Effects 0.000 claims 2
- 239000000227 bioadhesive Substances 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 235000010417 guar gum Nutrition 0.000 claims 2
- 239000000665 guar gum Substances 0.000 claims 2
- 229960002154 guar gum Drugs 0.000 claims 2
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 235000010420 locust bean gum Nutrition 0.000 claims 2
- 239000000711 locust bean gum Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 150000004804 polysaccharides Chemical class 0.000 claims 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims 2
- 239000011118 polyvinyl acetate Substances 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- 229940033134 talc Drugs 0.000 claims 2
- 235000012222 talc Nutrition 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- 229920001285 xanthan gum Polymers 0.000 claims 2
- 235000010493 xanthan gum Nutrition 0.000 claims 2
- 239000000230 xanthan gum Substances 0.000 claims 2
- 229940082509 xanthan gum Drugs 0.000 claims 2
- 239000005019 zein Substances 0.000 claims 2
- 229940093612 zein Drugs 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 244000215068 Acacia senegal Species 0.000 claims 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 108010076119 Caseins Proteins 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 claims 1
- 229920002284 Cellulose triacetate Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229920002148 Gellan gum Polymers 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 239000004348 Glyceryl diacetate Substances 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 229920001283 Polyalkylene terephthalate Polymers 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 240000004584 Tamarindus indica Species 0.000 claims 1
- 235000004298 Tamarindus indica Nutrition 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 108010055615 Zein Proteins 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 239000002280 amphoteric surfactant Substances 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000003945 anionic surfactant Substances 0.000 claims 1
- 239000000378 calcium silicate Substances 0.000 claims 1
- 229910052918 calcium silicate Inorganic materials 0.000 claims 1
- 229960003340 calcium silicate Drugs 0.000 claims 1
- 235000012241 calcium silicate Nutrition 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 239000005018 casein Substances 0.000 claims 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 1
- 235000021240 caseins Nutrition 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229920006218 cellulose propionate Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000011247 coating layer Substances 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 235000019443 glyceryl diacetate Nutrition 0.000 claims 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
- 229940075529 glyceryl stearate Drugs 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 229920001600 hydrophobic polymer Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000007942 layered tablet Substances 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000000391 magnesium silicate Substances 0.000 claims 1
- 229910052919 magnesium silicate Inorganic materials 0.000 claims 1
- 235000019792 magnesium silicate Nutrition 0.000 claims 1
- 229960002366 magnesium silicate Drugs 0.000 claims 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 230000003232 mucoadhesive effect Effects 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000003605 opacifier Substances 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 229920000111 poly(butyric acid) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920001281 polyalkylene Polymers 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 229920001444 polymaleic acid Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 229920001290 polyvinyl ester Polymers 0.000 claims 1
- 229920001289 polyvinyl ether Polymers 0.000 claims 1
- 229920001291 polyvinyl halide Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 238000009495 sugar coating Methods 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
- 239000002888 zwitterionic surfactant Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (24)
1. Oralni farmaceutski pripravak s kontroliranim oslobađanjem, koji se sastoji od višeslojne tablete naznačen time da se najmanje jedan sloj sastoji od polimera za kontrolu oslobađanja i rifaksimina ili farmaceutski prihvatljive (prihvatljivih) soli ili njihovih enantiomera ili polimorfa i da se najmanje jedan sloj sastoji od nekog bioadhezivnog polimera, pri čemu svaki sloj uključuje jednu ili više pomoćnih tvari.
2. Oralni farmaceutski pripravak s kontroliranim oslobađanjem prema zahtjevu 1, naznačen time da je taj pripravak formuliran na način da se produlji vrijeme zadržavanja rifaksimina u probavnom sustavu.
3. Oralni farmaceutski pripravak s kontroliranim oslobađanjem prema zahtjevu 2, naznačen time da se produljenje vremena zadržavanja rifaksimina u probavnom sustavu postiže bioadhezijom.
4. Oralni farmaceutski pripravak s kontroliranim oslobađanjem prema zahtjevu 1, naznačen time da se bioadhezija postiže polimerima koji imaju afinitet prema sluznici probavnog sustava a odabiru se između polikarbofila, karbomera, lektina, pektina, zeina, modificiranog zeina, kazeina, želatine, glutena, serumskog albumina, kolagena, hitozana, oligosaharida i polisaharida kao što je celuloza i njeni derivati kao što je metil celuloza, etil celuloza, hidroksipropil celuloza, hidroksipropilmetil celuloza, hidroksibutilmetil celuloza, celulozni acetat, celulozni propionat, celulozni acetat butirat, celulozni acetat ftalat, karboksimetil celuloza, celulozni triacetat, celulozni sulfat natrijeva sol, dekstrani, polisaharid iz sjemenski tamarinda, gelan, karagenan; hijaluronska kiselina, polihijaluronska kiselina, alginska kiselina, natrijev alginat; gume kao što su ksantanska guma, guar guma, gumi-arabika, guma od sjemenki rogača; polivinil acetat, polivinil alkohol, povidon/polietilen oksid, akrilna i metakrilna kiselina i njihovi kopolimeri, poliamidi, polikarbonati, polialkileni, polialkilen glikoli, polialkilen oksidi, polialkilen tereftalati, polivinil alkoholi, polivinil eteri, polivinil esteri, polivinil halidi, polivinil pirolidon, poliglikolidi, polisiloksani, poliuretani, polistiren, polimeri akrilnih i metakrilnih estera, polilaktidi, poli(buterna kiselina), poli(valerijanska kiselina), poli(laktid-ko-glikolid), polianhidridi, poliortoesteri, poli(fumarna kiselina), poli(maleična kiselina), polimeri koji imaju hidrofobnu okosnicu s najmanje jednom bočnom hidrofilnom skupinom, polimeri koji imaju hidrofobnu okosnicu s najmanje jednom bočnom hidrofobnom skupinom, te smjese i kopolimeri ili mješavine istih.
5. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1, naznačen time da polimer za kontrolu oslobađanja u sebi sadrži hidrofilni polimer za kontrolu brzine oslobađanja ili hidrofobni polimer za kontrolu brzine oslobađanja i kombinacije istih.
6. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 5, naznačen time da se hidrofilni polimer za regulaciju brzine oslobađanja odabire između ugljikohidrata poput celuloze, kao što je etil celuloza, hidroksipropil celuloza, hidroksipromilmetil celuloza, hidroksipropiletil celuloza; gume poput ksantanske gume, guar gume, gume iz sjemenki rogača; alginata; ugljika, polivinil acetata, polivinil alkohola, povidon/polietilen oksida, kopolimera akrilne i metakrilne kiseline ili mješavina istih.
7. Oralni farmaceutski pripravak s kontroliranim oslobađanjem prema zahtjevu 1, naznačen time da nadalje sadrži sredstvo (sredstva) za otapanje koja se odabiru između surfaktanata kao što su neionske, semipolarne, anionske, kationske, amfoterne ili zwitterionske površinski aktivne tvari topive u vodi; ciklodekstrin i njegovi derivati; lipofilne tvari; vitamin E i njegovi derivati; esteri nižih alkohola i masnih kiselina; otapala koja sadrže dušik; fosfolipidi; glicerol acetati kao što su acetin, diacetin i triacetin, esteri glicerola i masne kiselina kao što su mono-, di- i trigliceridi te acetilirani mono- i digliceridi; esteri propilen glikola; esteri etilen glikola ili bilo koja kombinacija istih.
8. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1, naznačen time da se farmaceutski prihvatljive pomoćne tvari odabiru između sredstava za vezivanje, razrjeđivanje, podmazivanje, površinski aktivnih tvari ili tvari za postizanje klizavosti.
9. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 8, naznačen time da je vezivno sredstvo jedno ili više njih, odabranih između ugljikohidrata kao što su celuloze; škrobovi; gume; polivinil pirolidon, povidon, sirup, polietilen oksid, poliakril amid, poli-N-vinil amid, natrij karbosimetil celuloza, polietilen glikol, želatina, polietilen oksid, polipropilen glikol, tragakant, alginska kiselina ili kombinacije istih.
10. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 8, naznačen time da je sredstvo za razrjeđivanje jedno ili više njih, odabranih između ugljikohidrata, derivata ugljikohidrata, poliola, šećernih alkohola, karbonatnih, sulfatnih ili fosfatnh soli anorganskih metala ili mješavine istih.
11. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 8, naznačen time da je sredstvo za podmazivanje jedno ili više njih, odabranih između magnezijevog, aluminijevog, cinkovog ili kalcijevog stearata, natrij stearil fumarata, polietilen glikola, mineralnog ulja, stearinske kiseline, hidrogeniziranog biljnog ulja, gliceril behenata, gliceril palmitostearata, gliceril stearata, kukuruznog škroba, talka, kalcijevog silikata, magnezijevog silikata, koloidnog silicijevog dioksida, silicijevog hidrogela ili mješavina istih.
12. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 8, naznačen time da je površinski aktivna tvar jedna ili više njih, odabranih između ionskih ili neionskih ili zwitterionskih površinski aktivnih tvari.
13. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 8, naznačen time da je tvar za postizanje klizavosti jedna ili više njih, odabranih između silicijevog dioksida, koloidne silike, celuloze u prahu, talka, trobaznog kalcijevog fosfata ili mješavina istih.
14. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da je u obliku jednokratne dnevne doze.
15. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da je u obliku jednokratne dnevne doze koja sadrži 20 do 2400mg rifaksimina.
16. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da je u obliku jednokratne dnevne doze koja sadrži 550mg rifaksimina.
17. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da je u obliku jednokratne dnevne doze koja sadrži 600mg rifaksimina.
18. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da služi za povećanje spremnosti pacijenta za liječenje putnih proljeva, hepatičke encefalopatije, zaraznih proljeva, divertikularne bolesti, za antibakterijsku profilaksu prije operacije debelog crijeva, za liječenje sindroma nadražljivih crijeva, Crohnove bolesti, proljeva uzrokovanog bakterijom Clostridium difficile, prekomjernog broja bakterija u tankom crijevu, za profilaksu putnih proljeva, za liječenje dizenterije, pouchitisa (upale kirurški oblikovane crijevne vrećice), za predoperativnu profilaksu i za liječenje želučane dispepsije.
19. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da je za uporabu u liječenju putnih proljeva, hepatičke encefalopatije, zaraznih proljeva, divertikularne bolesti, za antibakterijsku profilaksu prije operacije debelog crijeva, za liječenje sindroma nadražljivih crijeva, Crohnove bolesti, proljeva uzrokovanog bakterijom Clostridium difficile, prekomjernog broja bakterija u tankom crijevu, za profilaksu putnog proljeva, za liječenje dizenterije, pouchitisa (upale kirurški oblikovane crijevne vrećice), za predoperativnu profilaksu i za liječenje želučane dispepsije.
20. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1, naznačen time da je za uporabu u liječenju putnih proljeva.
21. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1, naznačen time da je za uporabu u liječenju putnih proljeva kojima je uzročnik E. coli.
22. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 14, naznačen time da je za uporabu u liječenju putnih proljeva kojima je uzročnik Klebsiella.
23. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da dodatno je obložen pri čemu ta obloga uključuje film, šećerni premaz, enterički premaz, bioadhezivni ili mukoadhezivni premaz.
24. Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 23, naznačen time da sloj obloge sadrži sredstva za oblaganje, plastifikatore, sredstva protiv sljepljivanja, površinski aktivne tvari, bojila, sredstva za postizanje neprozirnosti ili mješavine istih.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN968KO2007 | 2007-07-06 | ||
EP08252158 | 2008-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120665T1 true HRP20120665T1 (hr) | 2012-10-31 |
Family
ID=40091777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120665AT HRP20120665T1 (hr) | 2007-07-06 | 2012-08-17 | Farmaceutski pripravci od rifaksimina |
Country Status (8)
Country | Link |
---|---|
EP (4) | EP2011486B2 (hr) |
CY (1) | CY1113068T1 (hr) |
DK (1) | DK2011486T3 (hr) |
ES (3) | ES2798253T3 (hr) |
HR (1) | HRP20120665T1 (hr) |
PL (1) | PL2011486T5 (hr) |
PT (1) | PT2011486E (hr) |
SI (1) | SI2011486T1 (hr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
DK1698630T3 (da) | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
EP3620153A1 (en) * | 2007-07-06 | 2020-03-11 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
SI3628319T1 (sl) | 2008-10-02 | 2024-04-30 | Salix Pharmaceuticals, Ltd. | Zdravljenje jetrne encefalopatije z rifaksiminom |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
MX2011013427A (es) * | 2009-06-15 | 2012-04-20 | Salix Pharmaceuticals Ltd | Modulacion de exposicion sistemica a rifaximina. |
KR20200100215A (ko) * | 2009-10-27 | 2020-08-25 | 루핀 리미티드 | 리팍시민의 고형 분산물 |
US9018684B2 (en) | 2009-11-23 | 2015-04-28 | California Institute Of Technology | Chemical sensing and/or measuring devices and methods |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
CN103228662B (zh) * | 2010-07-12 | 2016-08-10 | 萨利克斯药品有限公司 | 利福昔明的制剂及其用途 |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
WO2014033077A1 (en) | 2012-08-28 | 2014-03-06 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets |
ES2621557T3 (es) * | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
ES2742106T3 (es) | 2014-05-12 | 2020-02-13 | Alfasigma Spa | Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma |
WO2018064472A1 (en) * | 2016-09-30 | 2018-04-05 | Salix Pharmaceuticals, Ltd. | Solid dispersion forms of rifaximin |
CA3013161C (en) | 2017-04-26 | 2020-03-24 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
US11129862B2 (en) | 2017-08-30 | 2021-09-28 | Johnson & Johnson Consumer Inc. | Ophthalmic compositions |
CN108658673A (zh) * | 2018-06-27 | 2018-10-16 | 安徽瑞然生物药肥科技有限公司 | 一种用于缓释肥料的包膜材料及其制备方法 |
CN109021187B (zh) * | 2018-08-24 | 2019-09-06 | 中山大学 | 玉米醇溶蛋白-聚磺基甜菜碱两亲性缀合物及其制备方法与应用 |
CN109663150B (zh) * | 2018-12-29 | 2022-01-14 | 广州贝奥吉因生物科技股份有限公司 | 一种心肌修复水凝胶材料及其制备方法 |
WO2020208140A1 (en) | 2019-04-12 | 2020-10-15 | Sandoz Ag | Rifaximin-containing granules |
US20220378758A1 (en) * | 2019-09-24 | 2022-12-01 | Bausch Health Ireland Limited | Rifaximin liquid formulations |
CN111317824B (zh) * | 2020-02-29 | 2022-04-12 | 复旦大学 | 一种载多肽药物的口服纳米制剂及其制备方法 |
CA3184054A1 (en) * | 2020-06-26 | 2021-12-30 | Jacob Cole | Targeted release rifaximin compositions |
WO2023067485A1 (en) * | 2021-10-19 | 2023-04-27 | Zydus Lifesciences Limited | Pharmaceutical combinations |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
IT1253711B (it) * | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
IT1264494B1 (it) † | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
ITMI20041295A1 (it) † | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
US20060045865A1 (en) † | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
-
2008
- 2008-06-26 DK DK08252198.0T patent/DK2011486T3/da active
- 2008-06-26 ES ES11176043T patent/ES2798253T3/es active Active
- 2008-06-26 PL PL08252198.0T patent/PL2011486T5/pl unknown
- 2008-06-26 EP EP08252198.0A patent/EP2011486B2/en active Active
- 2008-06-26 EP EP14186563.4A patent/EP2837378A1/en not_active Withdrawn
- 2008-06-26 PT PT08252198T patent/PT2011486E/pt unknown
- 2008-06-26 SI SI200830741T patent/SI2011486T1/sl unknown
- 2008-06-26 EP EP20160395.8A patent/EP3714878B1/en active Active
- 2008-06-26 ES ES08252198.0T patent/ES2389358T5/es active Active
- 2008-06-26 ES ES20160395T patent/ES2905795T3/es active Active
- 2008-06-26 EP EP11176043.5A patent/EP2420226B1/en active Active
-
2012
- 2012-08-17 HR HRP20120665AT patent/HRP20120665T1/hr unknown
- 2012-08-23 CY CY20121100760T patent/CY1113068T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP3714878B1 (en) | 2022-01-19 |
PL2011486T3 (pl) | 2013-01-31 |
ES2389358T3 (es) | 2012-10-25 |
PL2011486T5 (pl) | 2016-09-30 |
EP2011486B1 (en) | 2012-05-23 |
ES2905795T3 (es) | 2022-04-12 |
EP3714878A1 (en) | 2020-09-30 |
PT2011486E (pt) | 2012-08-24 |
CY1113068T1 (el) | 2016-04-13 |
DK2011486T3 (da) | 2012-09-03 |
EP2837378A1 (en) | 2015-02-18 |
EP2420226A1 (en) | 2012-02-22 |
EP2011486A1 (en) | 2009-01-07 |
ES2389358T5 (es) | 2016-01-19 |
EP2420226B1 (en) | 2020-03-04 |
SI2011486T1 (sl) | 2012-10-30 |
ES2798253T3 (es) | 2020-12-10 |
EP2011486B2 (en) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120665T1 (hr) | Farmaceutski pripravci od rifaksimina | |
US20190076536A1 (en) | Pharmaceutical compositions for gastrointestinal drug delivery | |
JP5755878B2 (ja) | リファキシミンの薬剤組成物 | |
KR102198621B1 (ko) | 지연 방출형 약물 제형 | |
TWI736031B (zh) | 緩釋藥物配方 | |
WO2009047802A2 (en) | Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof | |
NO340155B1 (no) | Gastroresistente farmasøytiske formuleringer inneholdende rifaximin | |
JP2011500552A (ja) | 胃腸障害を処置するための医薬用組み合わせおよび組成物 | |
JPWO2017022248A1 (ja) | 腸溶性カプセル | |
JP6417532B2 (ja) | 放出制御医薬剤形 | |
JP5997034B2 (ja) | キトサン含有組成物及びキトサンコーティング組成物 | |
JP7391966B2 (ja) | 遅延放出製剤を製造する方法 | |
JP7423630B2 (ja) | 結腸ドラッグデリバリー製剤 | |
JP7321267B2 (ja) | 放出調節製剤のためのコーティング可能なコア | |
CA3122033A1 (en) | Colonic drug delivery formulation | |
JP2019052101A (ja) | 多層被覆製剤 |